Last checked at 8 Aug 2019 07:00
Diaceutics PLC
("Diaceutics" or the "Company")
Notice of results
Analyst briefing
Diaceutics PLC (AIM: DXRX), a provider of data analytics and implementation services to the global pharmaceutical industry, announces it will release its interim results for the six months ended 30 June 2019 on Monday 9 September 2019.
Analyst briefing
The Company will host a briefing for analysts which will take place at 11.30am on Monday 9 September 2019 in the City of London. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email diaceutics@walbrookpr.com.
Enquiries:
Diaceutics PLC | www.diaceutics.com | ||
Peter Keeling, Chief Executive Officer | via Walbrook PR | ||
Philip White, Chief Financial Officer |
| ||
|
| ||
Cenkos Securities plc (Nominated adviser and broker) | +44 (0) 20 3861 6630 | ||
Callum Davidson / Giles Balleny |
| ||
Michael Johnson (Sales) |
| ||
|
| ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com | ||
Anna Dunphy | Mob: +44 (0)7876 741 001 | ||
Paul McManus | Mob: +44 (0)7980 541 893 | ||
|
|
|
|
About Diaceutics
Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com